Skip to content

Abivax

  • EN
  • FR
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
  • EN
  • FR

News & Events

Press Coverage

  • 2023
  • 2022
  • 2021
  • 2020
  • 2019

BioWorld

May 3, 2017

Abivax shares surge as ABX-464 shows promise in draining HIV reservoirs

BioCentury

May 3, 2017

ABIVAX DOUBLES ON HIV RESERVOIR READOUT

LabioTech

May 3, 2017

French HIV Cure Reduces Viral Reservoirs for the First Time Ever

Reuters

April 4, 2017

Abivax initiates clinical trial (ABX464-005) to evaluate effect of ABX464 on HIV-reservoirs in HIV patients

The Pharma Letter

March 5, 2017

Market reaction reflects interest in Abivax HIV breakthrough

  • 1
  • …
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46

References available upon request.

© 2025 All rights reserved by Abivax 07/2024 Privacy and Terms of Use
Consent Preferences
  • About Abivax
    • Our Mission
    • Company History
    • Our Leadership
    • Contact Us
  • Our Science
    • Novel MOA
    • Obefazimod
  • Our Research
  • Our Pipeline
  • Publications
  • Investors
    • Overview
    • Press Releases
    • News
    • Share Price
    • Investor Documents
    • General Meeting
    • Corporate Presentation
Contact Us
  • Follow us on Twitter
  • Follow us on LinkedIn